EuGeni COVID-19 Antigen Rapid Test. Source: AnteoTech
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anteotech (ADO) successfully registers its updated EuGeni COVID-19 Rapid Antigen Test (RAT) in Europe under In Vitro Diagnostic Directive (IVDD) regulations
  • The new registration strengthens the product’s competitive position as it broadens the sampling methods available to detect COVID-19
  • Anteotech says this will also provide additional leverage as the company expands the RAT’s footprint in Europe
  • The company currently has a European trial underway evaluating the updated multiple-use claim to enable it to be included in the EU Common List registration application
  • Shares in Anteotech are up 27.66 per cent to 12 cents each at 10:53 am AEST.

Anteotech (ADO) has successfully registered its updated EuGeni COVID-19 Rapid Antigen Test (RAT) in Europe under In Vitro Diagnostic Directive (IVDD) regulations.

The new registration is for the same core Anteotech rapid diagnostic test registered in April 2021 but now covers multiple use claims to include combined nose and throat sampling and nasal mid-turbinate sampling on top of the original nasopharyngeal sampling method.

To establish the new use claims, the company completed analytical and clinical performance evaluations in the US and the UK, respectively, that focussed on validating the test’s effectiveness in detecting the Omicron variant of COVID-19.

The company said the new registration strengthened the RAT product’s competitive position as it broadened and aligned sampling methods to current trends in standard of care for the European market.

The updated test will also provide additional leverage as Anteotech expands the RAT’s footprint in Europe.

The company currently has a European Clinical Trial underway evaluating the updated multiple-use claim to enable this to be included in the EU Common List registration application.

AnteoTech said as it received orders for the updated multiple-use claim test kits, the original nasopharyngeal test would be phased out.

Shares in Anteotech were up 27.66 per cent to 12 cents each at 10:53 am AEST.

ADO by the numbers
More From The Market Herald
The Market Herald Video

" CI Resources (ASX:CII) buys 60pc interest in Singapore fertiliser trader for $4.4m

Phosphate specialist CI Resources (ASX:CII) has officially completed its $4.4 million purchase of a 60 per…
The Market Herald Video

" Paradigm Biopharmaceuticals (ASX:PAR) activates first UK site for phase three clinical trial

Paradigm Biopharmaceuticals (ASX:PAR) has activated its first trial site in the United Kingdom for a third-phase…
The Market Herald Video

" Inca Minerals (ASX:ICG) announces board restructure

Inca Minerals (ASX:ICG) yesterday announced a restructure to its board, with Adam Taylor appointed as Chairman.
Cavalier Resources (ASX:CVR) - Executive Technical Director, Daniel Tuffin

" Cavalier Resources (ASX:CVR) begins PFS at Crawford

Cavalier Resources (ASX:CVR) has begun a pre-feasibility study (PFS) at the Crawford Gold Project within the…